A role for IGF-1R-targeted therapies in small-cell lung cancer?

Gately, K., Collins, I., Forde, L., Al-Alao, B., Young, V., Gerg, M., Feuerhake, F., & O'Byrne, Kenneth J. (2011) A role for IGF-1R-targeted therapies in small-cell lung cancer? Clinical Lung Cancer, 12(1), pp. 38-42.

View at publisher

Abstract

Background: Small-cell lung cancer (SCLC) is an aggressive disease with a poor prognosis. The insulin-like growth factor-1 receptor (IGF-1R) is an autocrine growth factor and an attractive therapeutic target in many solid tumors, but particularly in lung cancer.

Patients and Methods: This study examined tumor samples from 23 patients diagnosed with SCLC, 11 resected specimens and 12 nodal biopsies obtained by mediastinoscopy, for expression of IGF-1R using the monoclonal rabbit anti-IGF-1R (clone G11, Ventana Medical Systems, Tucson, AZ) and standard immunohistochemistry (IHC).

Results: All 23 tumor samples expressed IGF-1R with a range of stain intensity from weak (1+) to strong (3+). Ten tumors had a score of 3+, 7 tumors 2+, and 6 tumors 1+. Patient survival data were available for all 23 patients. Two patients died < 30 days post biopsy, therefore, the intensity of anti-IGF-1R immunostaining for 21 patients was correlated to survival. Patients with 3+ immunostaining had a poorer prognosis (P = .003). The overall survival of patients who underwent surgical resection was significantly better (median survival not reached) than patients who were not resected (median survival, 7.4 months) (P = .006).

Conclusion: IGF-1R targeted therapies may have a role in the treatment of SCLC in combination with chemotherapy or as maintenance therapy. Further studies on the clinical benefit of targeting IGF-1R in SCLC are needed.

Impact and interest:

6 citations in Scopus
Search Google Scholar™
4 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 65069
Item Type: Journal Article
Refereed: Yes
Additional URLs:
Keywords: Biomarker, Immunohistochemistry, somatomedin C receptor, adult, aged, article, cancer chemotherapy, cancer surgery, cancer survival, clinical article, controlled study, female, histopathology, human, human cell, human tissue, lobectomy, lung biopsy, lung resection, lung small cell cancer, maintenance therapy, male, mediastinoscopy, overall survival, prognosis, protein expression, survival rate, survival time, Western blotting, Blotting, Western, Humans, Kaplan-Meier Estimate, Lung Neoplasms, Middle Aged, Receptor, IGF Type 1, Small Cell Lung Carcinoma, Tumor Markers, Biological
DOI: 10.3816/CLC.2011.n.005
ISSN: 1525-7304
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2011 Elsevier.
Deposited On: 04 Dec 2013 00:46
Last Modified: 13 Mar 2014 05:42

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page